Tumour antigens, such as neoantigens arising from mutations, are presented more effectively by certain HLA alleles, such as HLA-A*03:01, which has been shown to present the mKRAS G12V peptide [44, 45]. This evidence concerns the gene HLA-A and neoplasm.